



Edgar Filing: Ultragenyx Pharmaceutical Inc. - Form 8-K

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

Item 1.01 Entry into a Material Definitive Agreement

On January 10, 2019, Ultragenyx Pharmaceutical Inc. (the “Company”) entered into a Third Lease Amendment (the “Amendment”) to the Lease (the “Lease”) between Dimension Therapeutics, Inc., a wholly-owned subsidiary of the Company, and Rivertech Associates II, LLC pursuant to which the Lease was assigned to the Company, the term was extended to December 31, 2023, and an additional 9,538 square feet of space was added to the Lease. The Amendment is effective as of December 31, 2018. The Lease, as amended by the Amendment, covers certain space located at 840 Memorial Drive, Cambridge, MA.

The foregoing description of the Amendment is qualified in its entirety by the full text of the Amendment, a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

\* \* \*

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 15, 2019      Ultragenyx Pharmaceutical Inc.

By: /s/ Shalini Sharp  
Shalini Sharp  
Executive Vice President, Chief Financial Officer

- 3 -